AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on Days -3 and -2.
Study NCT02114502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant (SCT)
Description: Stem cell transplant on Day 0.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg by vein twice a day from Day -9 PM to Day -2 PM.
Study NCT02854189 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oxford unicompartmental knee arthroplasty
Description: The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
Study NCT04611997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
Study NCT04611997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine Green
Description: Indocyanine Green Tracer Using in Laparoscopic Gastrectomy with Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant
Study NCT02235415 — intervention group
Intervention type: DRUG
Intervention: Motens® (lacidipine)
Study NCT03613194 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sampling
Description: After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~* Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~* Peritoneal liquid~* none tumoral peritoneum~* Portal blood~* Peripheral blood~* Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator.
Study NCT00003863 — intervention group
Intervention type: GENETIC
Intervention: comparative genomic hybridization
Study NCT00003863 — intervention group
Intervention type: GENETIC
Intervention: cytogenetic analysis
Study NCT00003863 — intervention group
Intervention type: GENETIC
Intervention: fluorescence in situ hybridization
Study NCT00003863 — intervention group
Intervention type: GENETIC
Intervention: gene rearrangement analysis
Study NCT05702957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole 2.5mg-7.5mg
Description: Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
Study NCT05702957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50mg-150mg
Description: Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
Study NCT00346034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 to 600mg/day
Study NCT02268773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin®
Study NCT02268773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid low dose
Study NCT02268773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid high dose
Study NCT00636922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001(Everolimus)
Description: In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
Study NCT00941681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: 50 mg MR CK-1827452 BID for 10 days
Study NCT00941681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: 37.5 mg IR CK-1827452 TID for 10 days
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 25%) Medium Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 30%) Slow Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 25%) Medium Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (KCR 40%) Slow Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 300 mg (ECR 20%) Fast Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 20%) Medium Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 30%) Slow Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (KCR 40%) Slow Release
Study NCT00941681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: 100 mg MR CK-1827452 BID for 10 days
Study NCT00464308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Study NCT00464308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP ER 400 mg (ECR 20%) Fast Release
Study NCT02192463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine immediate release (IR) 200 mg
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: 30 mL oral rinse four times a day from Day -9 until discharge.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 15 g four times a day, swished, gargled and spit on Day -9 until discharge.
Study NCT02114502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100 mg by vein or mouth three times a day from Day -1.
Study NCT00124189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GRN163L
Description: Weekly intravenous infusion
Study NCT00450879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT00450879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Correlative studies
Study NCT00450879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00450879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03159390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phenylacetate salt of ornithine
Study NCT01357499 — intervention group
Intervention type: DEVICE
Intervention: blood pressure cuff
Description: A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
Study NCT01357499 — intervention group
Intervention type: DEVICE
Intervention: blood pressure cuff + electric muscle stimulator
Description: A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
Study NCT00716599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: training in use of rapid diagnostic tests (RDTs) for malaria
Description: training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
Study NCT00816998 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
Study NCT00816998 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Physical Therapy
Description: Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
Study NCT03903289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated red cell exchange
Description: Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.
Study NCT03903289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual red cell exchange
Description: Active Comparator: Manual red cell exchange
Study NCT00964756 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5.SSTR/TK.RGD
Description: Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
Study NCT00964756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV)
Description: GVC Day 5-18 IV 5 mg/kg BID all groups
Study NCT02423447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electro-Flo Intervention
Description: An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
Study NCT02423447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G5 Intervention
Description: An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
Study NCT03903289 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Simple red cell transfusion
Description: Active Comparator: Simple red cell transfusion
Study NCT04683861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: Paddle-shaped Spinal cord stimulation electrode with 16 contacts (AdaptiveStim® 39, 565; Medtronic, USA) will be implanted into the epidural space at the thoracic levels ranging from T10 to T12.
Study NCT01797874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Experimental
Study NCT01797874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo arm
Study NCT00464308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 40mg once daily for 28days - 1 placebo tab/cap \& 1 active tab/cap daily
Study NCT02656875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV130
Study NCT00396981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Matrix 2® coils for endovascular aneurysm occlusion
Description: endovascular aneurysm occlusion coil
Study NCT00396981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GDC® coils for endovascular aneurysm occlusion
Description: endovascular aneurysm occlusion coil
Study NCT04500054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: The music type was chosen by the patients and researchers did not have any influence on their choices.
Study NCT03635060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Bridge Plating
Description: This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
Study NCT03635060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar locking plating
Description: This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
Study NCT00693056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (w/o API)
Study NCT00693056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100 5mg
Description: 5 mg/dose of RX-10100
Study NCT00693056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100 10mg
Description: 10 mg/dose of RX-10100
Study NCT00693056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100 15mg
Description: 15 mg/dose of RX-10100
Study NCT00088218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: 1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
Study NCT00088218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C
Description: 20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
Study NCT02552394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: huJ591
Description: HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
Study NCT01112085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.05mg
Description: Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
Study NCT03442309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver diamine fluoride (SDF)
Study NCT03442309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)
Study NCT03442309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnishes
Description: Fluoride varnish (FV)
Study NCT01112085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg
Description: Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
Study NCT01546493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
Study NCT03442309 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Glass Ionomer Sealants (GC Fuji IX)
Study NCT02078778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: 3 months of CPAP treatment
Study NCT04238130 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Perioperative ctDNA Dynamic Monitoring
Description: To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline
Study NCT04433247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led Group Intervention
Description: Four week dissonance-based program wherein women with body image concerns complete verbal, written, and behavioral activities. The program consist of four 60-minute sessions.
Study NCT00720304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
Study NCT00720304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
Study NCT00720304 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
Study NCT00720304 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
Study NCT00720304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
Study NCT00720304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
Study NCT00720304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
Study NCT00720304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
Study NCT00720304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
Study NCT00720304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT00720304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
Study NCT05738083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Leaning Models
Description: Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance.~Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made.~Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes.~Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model.~Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model.
Study NCT02444741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT02444741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02444741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02444741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV